Cover Image
市場調查報告書

成癮:開發平台分析

Addiction - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 227550
出版日期 內容資訊 英文 369 Pages
訂單完成後即時交付
價格
Back to Top
成癮:開發平台分析 Addiction - Pipeline Review, H2 2015
出版日期: 2015年12月30日 內容資訊: 英文 369 Pages
簡介

所謂成癮,是指身體和心理戒斷症狀不得不常備著藥物的狀態。症狀為,必須反復使用藥物而無法完成職場和學校、家庭的工作、失眠、異常的時間醒來、異常疲倦、食慾不振或過剩、飲食習慣的變化、手掌冷或微出汗、手顫抖、眼變紅濕潤、瞳孔比平常放大縮小、呼吸和身體、服裝有異樣臭味等。

本報告提供成癮的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等,也夾雜最新的新聞和發表。

簡介

  • 調查範圍
  • 成癮 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

在企業正在開發的治療藥

在大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

在企業開發中的產品

在大學/機關研究中的產品

治療藥開發作的企業

  • AbbVie Inc.
  • Acura Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd
  • Adial Pharmaceuticals, LLC
  • Alkermes Plc
  • Aphios Corporation
  • Aradigm Corporation
  • Arena Pharmaceuticals, Inc.
  • Astraea Therapeutics, LLC
  • AstraZeneca PLC
  • Beech Tree Labs, Inc.
  • BioDelivery Sciences International, Inc.
  • Bionex Pharmaceuticals LLC
  • Bioprojet SCR
  • Camurus AB
  • Celtic Pharmaceutical Holdings L.P.
  • Cerecor Inc.
  • Curemark, LLC
  • D&A Pharma SAS
  • Eli Lilly and Company
  • Embera NeuroTherapeutics, Inc.
  • Euthymics Bioscience, Inc.
  • Foresee Pharmaceuticals, LLC
  • FORUM Pharmaceuticals Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Heptares Therapeutics Ltd.
  • Immunovaccine, Inc.
  • Indivior PLC
  • INSYS Therapeutics, Inc.
  • Invion Limited
  • Johnson & Johnson
  • Kyorin Pharmaceutical Co., Ltd.
  • Lightlake Therapeutics Inc.
  • Lohocla Research Corporation
  • MAKScientific, LLC
  • NAL Pharmaceuticals Ltd.
  • Nanotherapeutics, Inc.
  • Omeros Corporation
  • Pfizer Inc.
  • Relmada Therapeutics, Inc.
  • Rottapharm SpA
  • Royalty Pharma
  • Selecta Biosciences, Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • Sun Pharma Advanced Research Company Ltd.
  • Targacept, Inc.
  • Tekmira Pharmaceuticals Corp.
  • Teva Pharmaceutical Industries Limited
  • Titan Pharmaceuticals, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • VM Discovery, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (buprenorphine hydrochloride + naloxone hydrochloride)
  • (buprenorphine hydrochloride + naloxone hydrochloride)
  • (disulfiram + selegiline)
  • (oxazepam + metyrapone)
  • (topiramate + ondansetron hydrochloride)
  • ABT-436
  • ADX-71441
  • ADX-88178
  • AM-6527
  • amitifadine
  • Anatabine
  • Antisense Gene Therapy to Inhibit Aldehyde Dehydrogenase for Alcoholism
  • arbaclofen placarbil
  • ARD-1600
  • ASB
  • AT-1001
  • baclofen ER
  • BP-1.4979
  • BTL-ng
  • Buprenorphine Hemiadipate Hydrochloride
  • buprenorphine hydrochloride
  • buprenorphine hydrochloride
  • buprenorphine hydrochloride
  • buprenorphine hydrochloride depot
  • buprenorphine hydrochloride ER
  • buprenorphine hydrochloride SR
  • cannabidiol
  • cannabidiol
  • cannabidiol
  • carisbamate
  • CM-1212
  • CR-5542 Series
  • CR-5772 Series
  • dipraglurant IR
  • dronabinol
  • Drug for Dependence
  • Drug to Inhibit Triple Reuptake for Alcohol Dependence
  • Drugs to Activate HAT for CNS Disorders
  • Drugs to Inhibit FAAH for CNS Disorders
  • Drugs to Inhibit Histone Deacetylase for CNS Disorders
  • Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders
  • encenicline hydrochloride
  • FP-004
  • FP-007
  • GET-73
  • GS-6637
  • GSK-598809
  • ibudilast
  • JNJ-31020028
  • JNJ-5234801
  • lorcaserin hydrochloride
  • LT-22
  • LY-2456302
  • LY-2940094
  • MAL
  • methadone IR
  • methoxycoronaridine
  • nadolol
  • naltrexone
  • naltrexone
  • NIC7-DT
  • nicotine
  • nicotine
  • Nicotine Vaccine
  • NOX-B11
  • odelepran hydrochloride
  • OMS-405
  • OMS-527
  • ondansetron hydrochloride
  • PF-04457845
  • PF-05402536
  • PF-06413367
  • PF-5006739
  • phantasmidine
  • RO-656570
  • samidorphan
  • saracatinib difumarate
  • SEL-068
  • SLV-330
  • Small Molecule for Central Nervous System
  • Small Molecule for Drug Addiction
  • Small Molecule for Smoking Cessation
  • Small Molecule for Smoking Cessation and Appetite Suppression
  • Small Molecule to Activate Kappa Opioid Receptor for CNS
  • Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation
  • Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation
  • Small Molecule to Antagonize Ghrelin for Alcoholism
  • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction
  • Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders
  • Small Molecule to Inhibit BRD for Cocaine Dependence
  • Small Molecule to Inhibit Kappa Opioid Receptor for CNS
  • Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders
  • Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation
  • Small Molecules to Agonize NOP for Pain and Alcohol Addiction
  • Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction
  • Small Molecules to Inhibit DAT and SERT for CNS Disorders
  • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders
  • Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation
  • Small Molecules to Inhibit NTR1 for Psychiatric Disorders
  • Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders
  • sodium oxybate IR
  • Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction
  • Synthetic Peptides to Target DOR, MOR and MRP-1 for Oncology and CNS Disorders
  • TA-CD
  • TKM-ALDH2
  • TV-1380
  • Vaccine for Cocaine Addiction
  • Vaccine for Cocaine Addiction
  • Vaccine for Methamphetamine Addiction
  • Vaccine for Nicotine Addiction
  • Vaccine for Nicotine Addiction
  • Vaccine for Opium Addiction
  • VMD-2202

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7068IDB

Summary

Global Markets Direct's, 'Addiction - Pipeline Review, H2 2015', provides an overview of the Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Addiction
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Addiction and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Addiction pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Addiction
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Addiction Overview
  • Therapeutics Development
    • Pipeline Products for Addiction - Overview
    • Pipeline Products for Addiction - Comparative Analysis
  • Addiction - Therapeutics under Development by Companies
  • Addiction - Therapeutics under Investigation by Universities/Institutes
  • Addiction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Addiction - Products under Development by Companies
  • Addiction - Products under Investigation by Universities/Institutes
  • Addiction - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Addex Therapeutics Ltd
    • Adial Pharmaceuticals, LLC
    • Aelis Farma S.A.S.
    • Alkermes Plc
    • Aphios Corporation
    • Aradigm Corporation
    • Arbutus Biopharma Corporation
    • Arena Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • Astraea Therapeutics, LLC
    • AstraZeneca Plc
    • BioDelivery Sciences International, Inc.
    • Bionex Pharmaceuticals LLC
    • Bioprojet SCR
    • C4X Discovery Limited
    • Camurus AB
    • Catalyst Biosciences, Inc.
    • Celtic Pharmaceutical Holdings L.P.
    • Cerecor Inc.
    • CoMentis, Inc.
    • Curemark, LLC
    • Eli Lilly and Company
    • Embera NeuroTherapeutics, Inc.
    • Ethypharm S.A.
    • Euthymics Bioscience, Inc.
    • Foresee Pharmaceuticals, LLC
    • FORUM Pharmaceuticals Inc.
    • Grunenthal GmbH
    • H. Lundbeck A/S
    • Heptares Therapeutics Limited
    • Heron Therapeutics, Inc.
    • Immunovaccine, Inc.
    • Indivior Plc
    • INSYS Therapeutics, Inc.
    • InterveXion Therapeutics LLC
    • Invion Limited
    • Johnson & Johnson
    • Kyorin Pharmaceutical Co., Ltd.
    • Lightlake Therapeutics Inc.
    • Lohocla Research Corporation
    • MAKScientific, LLC
    • Marinus Pharmaceuticals, Inc.
    • NAL Pharmaceuticals Ltd.
    • Neurocrine Biosciences, Inc.
    • Omeros Corporation
    • P2D Bioscience
    • Pfizer Inc.
    • Relmada Therapeutics, Inc.
    • Rottapharm SpA
    • Royalty Pharma
    • RTI International
    • Saniona AB
    • Selecta Biosciences, Inc.
    • SK Biopharmaceuticals Co., Ltd.
    • Stada Arzneimittel AG
    • Teva Pharmaceutical Industries Limited
    • Titan Pharmaceuticals, Inc.
    • Tonix Pharmaceuticals Holding Corp.
    • VM Discovery, Inc.
    • XenoPort, Inc.
    • Zynerba Pharmaceuticals, Inc.
  • Addiction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
    • (disulfiram + selegiline) - Drug Profile
    • (oxazepam + metyrapone) - Drug Profile
    • (samidorphan l-malate + buprenorphine hydrochloride) - Drug Profile
    • 18-MC - Drug Profile
    • 2E-2 - Drug Profile
    • 4P-003 - Drug Profile
    • 4P-007 - Drug Profile
    • 4P-008 - Drug Profile
    • A-705253 - Drug Profile
    • ABT-436 - Drug Profile
    • ADX-71441 - Drug Profile
    • ADX-71743 - Drug Profile
    • ADX-88178 - Drug Profile
    • AEF-0117 - Drug Profile
    • AM-6527 - Drug Profile
    • amitifadine - Drug Profile
    • Anatabine - Drug Profile
    • arbaclofen placarbil - Drug Profile
    • ASP-2905 - Drug Profile
    • AT-076 - Drug Profile
    • AT-089 - Drug Profile
    • AT-1001 - Drug Profile
    • AT-212 - Drug Profile
    • baclofen - Drug Profile
    • BP-1.4979 - Drug Profile
    • Buprenorphine Hemiadipate Hydrochloride - Drug Profile
    • buprenorphine hydrochloride - Drug Profile
    • buprenorphine hydrochloride - Drug Profile
    • buprenorphine hydrochloride - Drug Profile
    • buprenorphine hydrochloride depot - Drug Profile
    • buprenorphine hydrochloride ER - Drug Profile
    • buprenorphine hydrochloride long acting - Drug Profile
    • buprenorphine hydrochloride SR - Drug Profile
    • cannabidiol - Drug Profile
    • Cannabidiol - Drug Profile
    • cannabidiol - Drug Profile
    • carisbamate - Drug Profile
    • CERC-501 - Drug Profile
    • Ch-mAb7F9 - Drug Profile
    • CM-1212 - Drug Profile
    • Conjugate Vaccine for Methamphetamine Abuse - Drug Profile
    • CR-5542 Series - Drug Profile
    • dronabinol - Drug Profile
    • dronabinol - Drug Profile
    • Drug for Dependence - Drug Profile
    • Drug to Inhibit Triple Reuptake for Alcohol Dependence - Drug Profile
    • Drugs to Inhibit FAAH for CNS Disorders - Drug Profile
    • Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile
    • encenicline hydrochloride - Drug Profile
    • Enzyme for Cocaine Addiction - Drug Profile
    • EORA-101 - Drug Profile
    • FP-004 - Drug Profile
    • FP-007 - Drug Profile
    • gabapentin enacarbil XR - Drug Profile
    • ganaxolone - Drug Profile
    • Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile
    • GET-73 - Drug Profile
    • GTS-21 - Drug Profile
    • ibudilast - Drug Profile
    • JDTic - Drug Profile
    • JNJ-39393406 - Drug Profile
    • JNJ-5234801 - Drug Profile
    • JQ-1 - Drug Profile
    • lofexidine hydrochloride - Drug Profile
    • lorcaserin hydrochloride - Drug Profile
    • LT-22 - Drug Profile
    • MC-100093 - Drug Profile
    • N-S2359 - Drug Profile
    • nadolol - Drug Profile
    • nalmefene - Drug Profile
    • naltrexone hydrochloride - Drug Profile
    • naltrexone hydrochloride - Drug Profile
    • naltrexone hydrochloride - Drug Profile
    • NFL-101 - Drug Profile
    • NIC7-DT - Drug Profile
    • nicotine - Drug Profile
    • nicotine - Drug Profile
    • nicotine - Drug Profile
    • Nicotine Vaccine - Drug Profile
    • Noribogaine - Drug Profile
    • odelepran hydrochloride - Drug Profile
    • OMS-405 - Drug Profile
    • OMS-527 - Drug Profile
    • ondansetron hydrochloride - Drug Profile
    • PF-04457845 - Drug Profile
    • PF-05402536 - Drug Profile
    • PF-06413367 - Drug Profile
    • PF-5006739 - Drug Profile
    • phantasmidine - Drug Profile
    • RBP-8000 - Drug Profile
    • Recombinant Enzyme for Cocaine Abuse - Drug Profile
    • RO-656570 - Drug Profile
    • samidorphan l-malate - Drug Profile
    • saracatinib difumarate - Drug Profile
    • SEL-068 - Drug Profile
    • Small Molecule for Drug Addiction - Drug Profile
    • Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile
    • Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile
    • Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
    • Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile
    • Small Molecule to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile
    • Small Molecule to Antagonize Dopamine D1, D2 and D3 Receptors for Cocaine Use Disorder - Drug Profile
    • Small Molecule to Antagonize Ghrelin for Alcoholism - Drug Profile
    • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile
    • Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS - Drug Profile
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
    • Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
    • Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
    • Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile
    • Small Molecules to Agonize NTR1 for Psychiatric Disorders and Addiction - Drug Profile
    • Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile
    • Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile
    • Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
    • Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile
    • Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
    • Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
    • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
    • Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile
    • Small Molecules to Target 5HT2 for CNS and Metabolic Disorders - Drug Profile
    • Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile
    • Stem Cell Therapy to Activate DAT for Schizophrenia and Addictive Disorders - Drug Profile
    • Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile
    • Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile
    • Synthetic Peptides to Target DOR, MOR and MRP-1 for Oncology and CNS Disorders - Drug Profile
    • TA-CD - Drug Profile
    • TKM-ALDH2 - Drug Profile
    • TV-1380 - Drug Profile
    • Vaccine for Cocaine Addiction - Drug Profile
    • Vaccine for Drug Abuse - Drug Profile
    • Vaccine for Methamphetamine Addiction - Drug Profile
    • Vaccine for Nicotine Addiction - Drug Profile
    • Vaccine for Nicotine Addiction - Drug Profile
    • Vaccine for Opium Addiction - Drug Profile
    • verucerfont - Drug Profile
    • VMD-2202 - Drug Profile
    • VU-0463841 - Drug Profile
  • Addiction - Recent Pipeline Updates
  • Addiction - Dormant Projects
  • Addiction - Discontinued Products
  • Addiction - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Addiction, H2 2015
  • Number of Products under Development for Addiction - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Addiction - Pipeline by AbbVie Inc., H2 2015
  • Addiction - Pipeline by Addex Therapeutics Ltd, H2 2015
  • Addiction - Pipeline by Adial Pharmaceuticals, LLC, H2 2015
  • Addiction - Pipeline by Aelis Farma S.A.S., H2 2015
  • Addiction - Pipeline by Alkermes Plc, H2 2015
  • Addiction - Pipeline by Aphios Corporation, H2 2015
  • Addiction - Pipeline by Aradigm Corporation, H2 2015
  • Addiction - Pipeline by Arbutus Biopharma Corporation, H2 2015
  • Addiction - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
  • Addiction - Pipeline by Astellas Pharma Inc., H2 2015
  • Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2015
  • Addiction - Pipeline by AstraZeneca Plc, H2 2015
  • Addiction - Pipeline by BioDelivery Sciences International, Inc., H2 2015
  • Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2015
  • Addiction - Pipeline by Bioprojet SCR, H2 2015
  • Addiction - Pipeline by C4X Discovery Limited, H2 2015
  • Addiction - Pipeline by Camurus AB, H2 2015
  • Addiction - Pipeline by Catalyst Biosciences, Inc., H2 2015
  • Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H2 2015
  • Addiction - Pipeline by Cerecor Inc., H2 2015
  • Addiction - Pipeline by CoMentis, Inc., H2 2015
  • Addiction - Pipeline by Curemark, LLC, H2 2015
  • Addiction - Pipeline by Eli Lilly and Company, H2 2015
  • Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2015
  • Addiction - Pipeline by Ethypharm S.A., H2 2015
  • Addiction - Pipeline by Euthymics Bioscience, Inc., H2 2015
  • Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015
  • Addiction - Pipeline by FORUM Pharmaceuticals Inc., H2 2015
  • Addiction - Pipeline by Grunenthal GmbH, H2 2015
  • Addiction - Pipeline by H. Lundbeck A/S, H2 2015
  • Addiction - Pipeline by Heptares Therapeutics Limited, H2 2015
  • Addiction - Pipeline by Heron Therapeutics, Inc., H2 2015
  • Addiction - Pipeline by Immunovaccine, Inc., H2 2015
  • Addiction - Pipeline by Indivior Plc, H2 2015
  • Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2015
  • Addiction - Pipeline by InterveXion Therapeutics LLC, H2 2015
  • Addiction - Pipeline by Invion Limited, H2 2015
  • Addiction - Pipeline by Johnson & Johnson, H2 2015
  • Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
  • Addiction - Pipeline by Lightlake Therapeutics Inc., H2 2015
  • Addiction - Pipeline by Lohocla Research Corporation, H2 2015
  • Addiction - Pipeline by MAKScientific, LLC, H2 2015
  • Addiction - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015
  • Addiction - Pipeline by NAL Pharmaceuticals Ltd., H2 2015
  • Addiction - Pipeline by Neurocrine Biosciences, Inc., H2 2015
  • Addiction - Pipeline by Omeros Corporation, H2 2015
  • Addiction - Pipeline by P2D Bioscience, H2 2015
  • Addiction - Pipeline by Pfizer Inc., H2 2015
  • Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2015
  • Addiction - Pipeline by Rottapharm SpA, H2 2015
  • Addiction - Pipeline by Royalty Pharma, H2 2015
  • Addiction - Pipeline by RTI International, H2 2015
  • Addiction - Pipeline by Saniona AB, H2 2015
  • Addiction - Pipeline by Selecta Biosciences, Inc., H2 2015
  • Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
  • Addiction - Pipeline by Stada Arzneimittel AG, H2 2015
  • Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
  • Addiction - Pipeline by Titan Pharmaceuticals, Inc., H2 2015
  • Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015
  • Addiction - Pipeline by VM Discovery, Inc., H2 2015
  • Addiction - Pipeline by XenoPort, Inc., H2 2015
  • Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Addiction Therapeutics - Recent Pipeline Updates, H2 2015
  • Addiction - Dormant Projects, H2 2015
  • Addiction - Dormant Projects (Contd..1), H2 2015
  • Addiction - Dormant Projects (Contd..2), H2 2015
  • Addiction - Dormant Projects (Contd..3), H2 2015
  • Addiction - Dormant Projects (Contd..4), H2 2015
  • Addiction - Dormant Projects (Contd..5), H2 2015
  • Addiction - Dormant Projects (Contd..6), H2 2015
  • Addiction - Dormant Projects (Contd..7), H2 2015
  • Addiction - Dormant Projects (Contd..8), H2 2015
  • Addiction - Dormant Projects (Contd..9), H2 2015
  • Addiction - Dormant Projects (Contd..10), H2 2015
  • Addiction - Dormant Projects (Contd..11), H2 2015
  • Addiction - Discontinued Products, H2 2015
  • Addiction - Discontinued Products (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for Addiction, H2 2015
  • Number of Products under Development for Addiction - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top